A Randomised, Active Comparator, Double-blind, Multi Centre, Parallel, Phase 2a Trial, Investigating the Mechanism of Action, of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
Price : $35 *
At a glance
- Drugs Fletikumab (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 22 Mar 2017 This trial has been discontinued in UK (End date:2014-08-11) as per European Clinical Trials Database.
- 13 Aug 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.